Clinical Trial Update: Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the addition of M3814 (peposertib), a DNA-PK inhibitor, to radiation therapy in patients with advanced head and neck squamous cell carc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Lip and Oral Cavity Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer

Drugs mentioned

• Peposertib (M3814) (peposertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING